STING Activation and its Application in Immuno-Oncology
- 18 November 2019
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 19 (24) , 2205-2227
Abstract
Recent regulatory approval of several immune checkpoint inhibitors has ushered in a new era of cancer immunotherapies with the promise of achieving a durable response. This represents a paradigm shift in cancer treatment from directly targeting tumor cells to harnessing the power of a patient’s own immune system to destroy them. The cGAS-STING pathway is the major cytosolic dsDNA sensing pathway that plays a pivotal role in the innate antitumor immune response. With a fundamentally different mode of action (MOA) than immune checkpoint modulators, STING activation can potentially enhance tumor immunogenicity and improve patient responses as a single agent or by synergizing with existing anti-cancer drugs. Therefore, there has been intense interest from the pharmaceutical industry and academic institutions in the search for potent STING agonists as immunotherapies in oncology. In this article, we review briefly the cGAS-STING pathway and STING agonists that are in the clinical and preclinical studies, summarize recently disclosed patent applications and published journal articles in the field and cover both cyclic dinucleotide (CDN) analogs and non-nucleic acid derived STING agonists.Keywords
This publication has 121 references indexed in Scilit:
- The Innate Immune DNA Sensor cGAS Produces a Noncanonical Cyclic Dinucleotide that Activates Human STINGCell Reports, 2013
- Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune systemNature Structural & Molecular Biology, 2012
- Coordinated Regulation of Accessory Genetic Elements Produces Cyclic Di-Nucleotides for V. cholerae VirulenceCell, 2012
- STING Specifies IRF3 Phosphorylation by TBK1 in the Cytosolic DNA Signaling PathwayScience Signaling, 2012
- STING is a direct innate immune sensor of cyclic di-GMPNature, 2011
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cellsJournal of Experimental Medicine, 2011
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsJournal of Experimental Medicine, 2011
- TheN-Ethyl-N-Nitrosourea-InducedGoldenticketMouse Mutant Reveals an Essential Function ofStingin theIn VivoInterferon Response toListeria monocytogenesand Cyclic DinucleotidesInfection and Immunity, 2011
- STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunityNature, 2009
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signallingNature, 2008